MedDataX Logo

URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol

NCT ID: NCT00392548

Last Updated: 2006-10-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

130 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-10-31

Study Completion Date

2006-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study of the urinary vascular endothelial growth factor (VEGF) levels in patients with glioblastoma, receiving standard therapy.

Hypothesis: that urinary VEGF levels can serve as a predictor of treatment response and survival.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Measurement of urinary VEGF levels pre treatment,immediately after treatment, and 1 month after treatment

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

GBM glioblastoma urine VEGF radiation Patients must be enrolled to an RTOG GBM study that prescribes 6000 cGy of radiation therapy.

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

DEFINED_POPULATION

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient must be enrolled on an RTOG GBM study that prescribes 6000 cGy of radiation therapy.
* Patient must meet the eligibility requirements for the RTOG treatment study. (If the patient is deemed retrospectively ineligible for the RTOG treatment study, the patient will likewise be ineligible for this study.)
* Patient must sign a study-specific informed consent for RTOG 0611 prior to study entry.

Exclusion Criteria

* Patient not able to receive 6000 cGy of radiation therapy.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Radiation Therapy Oncology Group

NETWORK

Sponsor Role collaborator

Tel-Aviv Sourasky Medical Center

OTHER_GOV

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Deborah T Blumenthal, MD

Role: PRINCIPAL_INVESTIGATOR

Tel-Aviv Sourasky Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Deborah T Blumenthal, MD

Role: CONTACT

Phone: 011972524266304

Email: [email protected]

Lina Vizelman, BS

Role: CONTACT

Phone: 01197236977532

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RTOG0611

Identifier Type: -

Identifier Source: org_study_id